Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate a Phase III Study of OH2 Versus Investigator-selected Salvage Chemotherapy or Best Supportive Care in Melanoma Patients Who Had Failed Standard Therapy

NCT05868707 is registered in ClinicalTrials.gov with Binhui Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05868707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05868707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate a Phase III Study of OH2 Versus Investigator-selected Salvage Chemotherapy or Best Supportive Care in Melanoma Patients Who Had Failed Standard Therapy
Lead sponsor
Binhui Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
March 8, 2023
Completion date
March 31, 2027
Enrollment
340 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma